Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIUMPH-3: Retatrutide in Severe Obesity with Established Cardiovascular Disease
2023-503659-88-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2023
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in obesity and cardiac morbidity comparing Retatrutide once weekly with Placebo once weekly (2 arms). Primary endpoint: Percent change from baseline in body weight. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
obesitycardiac morbidity
Beyond the preview
Go deeper on 2023-503659-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503659-88-00.